GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (STU:RDDA) » Definitions » Cyclically Adjusted Revenue per Share

Dr Reddy's Laboratories (STU:RDDA) Cyclically Adjusted Revenue per Share : €15.51 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dr Reddy's Laboratories's adjusted revenue per share for the three months ended in Jun. 2024 was €5.121. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €15.51 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Dr Reddy's Laboratories's average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Dr Reddy's Laboratories was 18.80% per year. The lowest was 5.80% per year. And the median was 8.50% per year.

As of today (2024-09-21), Dr Reddy's Laboratories's current stock price is €69.50. Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €15.51. Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is 4.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.89. The lowest was 2.27. And the median was 3.85.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Chart

Dr Reddy's Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.91 12.46 14.02 14.42 15.06

Dr Reddy's Laboratories Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.63 15.14 14.58 15.06 15.51

Competitive Comparison of Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio falls into.



Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dr Reddy's Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=5.121/155.7889*155.7889
=5.121

Current CPI (Jun. 2024) = 155.7889.

Dr Reddy's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 2.676 96.780 4.308
201412 2.908 96.780 4.681
201503 3.346 97.163 5.365
201506 3.069 99.841 4.789
201509 3.140 101.753 4.807
201512 3.202 102.901 4.848
201603 2.947 102.518 4.478
201606 2.518 105.961 3.702
201609 2.883 105.961 4.239
201612 3.122 105.196 4.623
201703 3.044 105.196 4.508
201706 2.758 107.109 4.011
201709 2.778 109.021 3.970
201712 3.013 109.404 4.290
201803 2.651 109.786 3.762
201806 2.828 111.317 3.958
201809 2.709 115.142 3.665
201812 2.876 115.142 3.891
201903 3.081 118.202 4.061
201906 2.952 120.880 3.805
201909 3.683 123.175 4.658
201912 3.345 126.235 4.128
202003 3.238 124.705 4.045
202006 3.118 127.000 3.825
202009 3.399 130.118 4.070
202012 3.308 130.889 3.937
202103 3.280 131.771 3.878
202106 3.339 134.084 3.879
202109 4.000 135.847 4.587
202112 3.755 138.161 4.234
202203 3.895 138.822 4.371
202206 3.798 142.347 4.157
202209 4.770 144.661 5.137
202212 4.657 145.763 4.977
202303 4.295 146.865 4.556
202306 4.542 150.280 4.708
202309 4.655 151.492 4.787
202312 4.765 152.924 4.854
202403 4.705 153.035 4.790
202406 5.121 155.789 5.121

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Dr Reddy's Laboratories  (STU:RDDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=69.50/15.51
=4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.89. The lowest was 2.27. And the median was 3.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories Business Description

Traded in Other Exchanges
Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories Headlines

No Headlines